Go back Arrow Left

Inauguration of the North Asia Medical Advisory Board

Inauguration of the North Asia Medical Advisory Board

NORTH ASIA MEDICAL ADVISORY BOARD NEWS:

 

With a mission to create positive impact for patients globally, ARCHIMED continues to expand its group of clinical and scientific experts who bring practical insight from the front line of clinical practice.

 

Following the successful launch of the North Asia Scientific Advisory Board (SAB) in April, ARCHIMED has now inaugurated the North Asia Medical Advisory Board (MAB). While the SAB brings a research perspective, the MAB is built around physicians actively practicing in the field, the people best placed to see how a device or treatment actually performs once it reaches patients. That perspective directly informs how ARCHIMED evaluates healthcare investments and how they translate into patient outcomes.

 

The MAB held its first meeting on June 29 in Tokyo. Seven clinical and scientific advisors and ARCHIMED’s investment and operational team convened for the first time in an active exchange. Each MAB member shared insight from their own field, and ARCHIMED offered exposure to its European medical advisory network.

 

Going forward, ARCHIMED and the MAB will continue their regular dialogue as new opportunities emerge, to create real impact for patients at a global level.

 

About the North Asia Medical Advisory Board

 

The board is made up of physicians and researchers drawn from ARCHIMED’s connections in Japan. Sharing a passion for medical innovation and what it means for patients, they bring expertise on clinical relevance, on how a product fits into practice, and on where the real unmet needs sit, and help shape the clinical value that ARCHIMED pursues. The board gives innovative insight into the medical and clinical space, reviews technologies and products that ARCHIMED is considering, and introduces ARCHIMED to domestic and international companies, key opinion leaders (KOLs), academic societies, and research institutions, helping ARCHIMED and its companies to contribute to global medical needs.

 

North Asia Medical Advisory Board Members

 

Dr. Masaaki Ito

  • Deputy Director, National Cancer Center Hospital East (Colorectal & Pelvic Surgery)

Dr. Kazuaki Kanemitsu

  • Head of Healthcare Excellence, Roche Diagnostics K.K.

Dr. Takashi Kunihara

  • Professor and Chair, Department of Cardiovascular Surgery, The Jikei University School of Medicine

Dr. Kiyokazu Nakajima

  • Professor, Department of Next Generation Endoscopic Intervention, The University of Osaka

Dr. Masato Nakamura

  • Professor, Division of Minimally Invasive Cardiology, Toho University Ohashi Medical Center

Dr. Koichiro Ono

  • Lecturer, Department of Orthopedics, Nippon Medical School

Dr. Hisao Tajiri

  • Former President, World Endoscopy Organization (WEO); Vice President, Asian Pacific Society for Digestive Endoscopy

Note: alphabetical order by last name

About ARCHIMED

archimed.group

With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €8 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.

ARCHIMED Press Contacts

Stéphanie du Ché
stephanie.duche@archimed.group
+33 (0)6 16 36 11 08

David Lanchner
dlanchner@lanchner.com,
+33 (0)6 33 43 50 76